1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
10qk
10qk
Articles 

Immucor Inc. Reports Operating Results (10-Q)

January 14, 2013 | About:

Immucor Inc. (BLUD) filed Quarterly Report for the period ended 2012-11-30.

.

Highlight of Business Operations:

Revenue was $167.2 million in the first six months of fiscal 2013 and $169.3 million in combined Successor and Predecessor same fiscal 2012 period, a decrease of $2.1 million. Fewer ship cycles and negative exchange rate fluctuations in the quarter ended November 30, 2012 negatively impacted revenue by $6.4 million when compared with the prior year period. Current year revenue was also negatively impacted by a $1.1 million reductions related to changes in purchase accounting deferred revenue related to the Acquisition. Normalizing for the impact of ship cycles, exchange rate fluctuations, and the reductions related to purchase accounting deferred revenue, revenue increased 3.2% when comparing the first six months of fiscal 2013 to the combined Successor and Predecessor same fiscal 2012 period.

Traditional reagent revenue for the quarter ended November 30, 2012 was $46.0 million compared to $47.7 million in the same period from prior year. Traditional reagent revenue is negatively impacted as we convert current manual customers to automation by placing an instrument. Instruments use approximately 70% Capture reagents and 30% Traditional reagents so placing an instrument results in an increase in Capture reagent revenue and a decrease in Traditional reagent revenue with a current customer. With our automation strategy, we expect this trend to continue. The $1.7 million decrease in revenue was driven primarily by weaker industry demand in the U.S. market and the impact of our automation strategy. Traditional reagent revenue was $93.0 million in the first six months of fiscal 2013 and $96.9 million in combined Successor and Predecessor fiscal 2012 period. Normalizing for the impact of ship cycles and exchange rate fluctuations (combined $2.3 million), the overall decrease would be 1.7% which was primarily due to lower industry demand in the U.S. market and the impact of our automation strategy partially offset by price contribution and increased volume outside of the U.S. market. Capture reagent revenue for the quarter ended November 30, 2012 was $20.8 million compared to the $22.4 million for the same period from prior year. Sales of Capture reagents are largely dependent on the number of installed instruments requiring the use of our proprietary Capture technology. As we continue to place more instruments in the market, we expect revenue from Capture reagents to increase as a percentage of our total revenue. Normalizing for the impact of ship cycles and exchange rate fluctuations (combined $2.5 million), Capture reagent revenue increased 4.0%. Capture reagent revenue for the first six month fiscal period of 2013 was $45.1 million compared to $46.9 million in the combined Successor and Predecessor fiscal 2012 period from prior year. Normalizing for the impact of ship cycles and exchange rate fluctuations (combined $3.4 million), Capture reagent revenue increased 3.4% resulting primarily from the Company s automation strategy. Instrument revenue for the quarter ended November 30, 2012 was $13.6 million compared to $11.5 million for the same period from prior year. The $2.1 million increase in revenue was primarily due to increased placements of instruments. Instrument revenue for the first six month fiscal period of 2013 was $25.8 million compared to $22.5 million in the combined Successor and Predecessor fiscal 2012 period from prior year. The increases in revenue for the quarterly comparisons and year to date fiscal periods were primarily due to increased placements of instruments. Molecular immunohematology revenue changed due to increased demand for both the quarterly and year to date fiscal period comparisons.

Traditional reagent revenue for the quarter ended November 30, 2012 was $46.0 million compared to $47.7 million in the same period from prior year. Traditional reagent revenue is negatively impacted as we convert current manual customers to automation by placing an instrument. Instruments use approximately 70% Capture reagents and 30% Traditional reagents so placing an instrument results in an increase in Capture reagent revenue and a decrease in Traditional reagent revenue with a current customer. With our automation strategy, we expect this trend to continue. The $1.7 million decrease in revenue was driven primarily by weaker industry demand in the U.S. market and the impact of our automation strategy. Traditional reagent revenue was $93.0 million in the first six months of fiscal 2013 and $96.9 million in combined Successor and Predecessor fiscal 2012 period. Normalizing for the impact of ship cycles and exchange rate fluctuations (combined $2.3 million), the overall decrease would be 1.7% which was primarily due to lower industry demand in the U.S. market and the impact of our automation strategy partially offset by price contribution and increased volume outside of the U.S. market.

Traditional reagent revenue for the quarter ended November 30, 2012 was $46.0 million compared to $47.7 million in the same period from prior year. Traditional reagent revenue is negatively impacted as we convert current manual customers to automation by placing an instrument. Instruments use approximately 70% Capture reagents and 30% Traditional reagents so placing an instrument results in an increase in Capture reagent revenue and a decrease in Traditional reagent revenue with a current customer. With our automation strategy, we expect this trend to continue. The $1.7 million decrease in revenue was driven primarily by weaker industry demand in the U.S. market and the impact of our automation strategy. Traditional reagent revenue was $93.0 million in the first six months of fiscal 2013 and $96.9 million in combined Successor and Predecessor fiscal 2012 period. Normalizing for the impact of ship cycles and exchange rate fluctuations (combined $2.3 million), the overall decrease would be 1.7% which was primarily due to lower industry demand in the U.S. market and the impact of our automation strategy partially offset by price contribution and increased volume outside of the U.S. market.

Capture reagent revenue for the quarter ended November 30, 2012 was $20.8 million compared to the $22.4 million for the same period from prior year. Sales of Capture reagents are largely dependent on the number of installed instruments requiring the use of our proprietary Capture technology. As we continue to place more instruments in the market, we expect revenue from Capture reagents to increase as a percentage of our total revenue. Normalizing for the impact of ship cycles and exchange rate fluctuations (combined $2.5 million), Capture reagent revenue increased 4.0%. Capture reagent revenue for the first six month fiscal period of 2013 was $45.1 million compared to $46.9 million in the combined Successor and Predecessor fiscal 2012 period from prior year. Normalizing for the impact of ship cycles and exchange rate fluctuations (combined $3.4 million), Capture reagent revenue increased 3.4% resulting primarily from the Company s automation strategy.

Read the The complete Report

About the author:

10qk
Charlie Tian, Ph.D., is the founder of GuruFocus. You can now order his book Invest Like a Guru on Amazon.

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by 10qk


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)